CORRECTION in appendix of interim condensed consolidated financial statements for the 12 months period ended 31 December 2019

On 28 February 2020 an announcement of Group’s 12 months 2019 financial results was made. During the design of the appendix several errors were made, incl. in financial data – in Profit for the reporting period 2018 (page 29), in section Property, plant and equipment (page 30), in section Non-current liabilities (page 31), in cash flow statement section Operating cash flows before working capital changes for 2019 (page 32), in statement of changes in equity in Share Premium column as at 31.12.2017. (page 33), in table Related party disclosures, line SIA Olmafarm as at 31.12.2019. in column Amounts owed by related parties (gross) (page 37), in table Segment information in line Segment profit before tax 12M 2019, column Unallocated and eliminated (page 38), in table Reconciliation of profit Unallocated financial income (page 38).

Financial data in is correct.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of the company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Additional information:  

Jānis Dubrovskis

Investor Relations Advisor of JSC Olainfarm

Phone:

Email: 

Attachment